Additional Study Information: The goal of the study is to learn if it is safe to give genetically changed T cells in combination with standard-of-care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of the study drug and if the study drug can help to control the disease. Cancers include bladder cancer, breast cancer, colon and rectal cancer, gynecologic cancers, liver cancer, lung cancer, skin cancer, pancreatic cancer, prostate cancer, stomach cancer, and thyroid cancer.